FR2244492A1 - - Google Patents

Info

Publication number
FR2244492A1
FR2244492A1 FR7432429A FR7432429A FR2244492A1 FR 2244492 A1 FR2244492 A1 FR 2244492A1 FR 7432429 A FR7432429 A FR 7432429A FR 7432429 A FR7432429 A FR 7432429A FR 2244492 A1 FR2244492 A1 FR 2244492A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7432429A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of FR2244492A1 publication Critical patent/FR2244492A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
FR7432429A 1973-09-26 1974-09-26 Withdrawn FR2244492A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19732349024 DE2349024A1 (de) 1973-09-26 1973-09-26 6beta,7beta-epoxy-1alpha,2alphamethylen-d-homo-4-pregnen-3,20-dione

Publications (1)

Publication Number Publication Date
FR2244492A1 true FR2244492A1 (fr) 1975-04-18

Family

ID=5894080

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7432429A Withdrawn FR2244492A1 (fr) 1973-09-26 1974-09-26

Country Status (16)

Country Link
US (1) US3965128A (fr)
JP (1) JPS5059362A (fr)
AR (1) AR202946A1 (fr)
AU (1) AU7374074A (fr)
BE (1) BE820381A (fr)
DD (1) DD114599A5 (fr)
DE (1) DE2349024A1 (fr)
DK (1) DK507974A (fr)
FI (1) FI280574A (fr)
FR (1) FR2244492A1 (fr)
IL (1) IL45629A0 (fr)
LU (1) LU70985A1 (fr)
NL (1) NL7412747A (fr)
NO (1) NO743449L (fr)
SE (1) SE7412058L (fr)
ZA (1) ZA746131B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022890A (en) * 1997-11-14 2000-02-08 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
AU1399199A (en) * 1997-11-14 1999-06-07 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
ES2821018T3 (es) 2009-04-22 2021-04-23 Resverlogix Corp Nuevos agentes antiinflamatorios
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242130B2 (en) 2004-10-20 2012-08-14 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8093273B2 (en) 2004-10-20 2012-01-10 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US9199990B2 (en) 2007-02-01 2015-12-01 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8889698B2 (en) 2007-02-01 2014-11-18 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US10532054B2 (en) 2007-02-01 2020-01-14 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US10131640B2 (en) 2009-03-18 2018-11-20 Resverlogix Corp. Anti-inflammatory agents
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US11407719B2 (en) 2009-03-18 2022-08-09 Resverlogix Corp. Anti-inflammatory agents
US10882828B2 (en) 2009-03-18 2021-01-05 Resverlogix Corp. Anti-inflammatory agents
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9278940B2 (en) 2012-11-21 2016-03-08 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10772894B2 (en) 2015-03-13 2020-09-15 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Also Published As

Publication number Publication date
DK507974A (fr) 1975-06-09
ZA746131B (en) 1975-09-24
NO743449L (fr) 1975-04-28
BE820381A (fr) 1975-03-26
NL7412747A (nl) 1975-04-01
US3965128A (en) 1976-06-22
LU70985A1 (fr) 1975-03-06
SE7412058L (fr) 1975-03-27
DD114599A5 (fr) 1975-08-12
IL45629A0 (en) 1974-11-29
JPS5059362A (fr) 1975-05-22
AR202946A1 (es) 1975-07-31
DE2349024A1 (de) 1975-04-10
AU7374074A (en) 1976-04-01
FI280574A (fr) 1975-03-27

Similar Documents

Publication Publication Date Title
AR201758A1 (fr)
AU476761B2 (fr)
AU465372B2 (fr)
AR201235Q (fr)
AR201231Q (fr)
AU474593B2 (fr)
AU474511B2 (fr)
AU474838B2 (fr)
AU465453B2 (fr)
AU471343B2 (fr)
AU465434B2 (fr)
AU450229B2 (fr)
AU476714B2 (fr)
AR201229Q (fr)
AU476696B2 (fr)
AU466283B2 (fr)
AU472848B2 (fr)
AR199451A1 (fr)
AU477823B2 (fr)
AR195311A1 (fr)
AU476873B1 (fr)
AU477824B2 (fr)
AR195948A1 (fr)
AU461342B2 (fr)
AR193950A1 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse